Corporate Financial Analysis: A Case on Square Pharmaceuticals Ltd.
PROSPECT ANALYSIS
Making a projection of the future is very challenging due to the uncertain future. The stock prices are very much interest sensitive as well as very quickly absorbing to any news in the market.
In brief, the prospect analysis of Square Pharma is based on the current and past data from 2011 to 2015.
A snap shot of the financial statements is given below:
BALANCE SHEET | |||||
2010-2011 | 2011-2012 | 2012-2013 | 2013-2014 | 2014-2015 | |
(Year) | (Year) | (Year) | (Year) | (Year) | |
Balance Sheet | |||||
Non Current Assets | 16,313,597,638 | 16,313,597,638 | 20,605,309,448 | 23,546,701,250 | 25,458,986,164.00 |
Current Assets: | 8,248,571,022 | 8,248,571,022 | 6,946,361,767 | 7,499,373,281 | 9,732,170,099.00 |
Total Assets | 24,562,168,660 | 24,562,168,660 | 27,551,671,215 | 31,046,074,531 | 35,191,156,263.00 |
Shareholders' Equity | 19,258,829,020 | 19,258,829,020 | 22,593,944,897 | 26,748,951,732 | 31,091,632,420.00 |
Non Current Liabilities | 987,949,283 | 987,949,283 | 1,682,318,885 | 1,902,585,673 | 1,550,505,777.00 |
Current Liabilities | 4,315,390,357 | 4,315,390,357 | 3,275,407,433 | 2,394,537,126 | 2,549,018,066.00 |
Book Value Per Share | 72.72 | 72.72 | 60.94 | 55.5 | 56.09 |
Total Liabilities & Shareholders Equity | 24,562,168,660 | 24,562,168,660 | 27,551,671,215 | 31,046,074,531 | 35,191,156,263.00 |
INCOME STATEMENT | |||||
2010-2011 | 2011-2012 | 2012-2013 | 2013-2014 | 2014-2015 | |
(Year) | (Year) | (Year) | (Year) | (Year) | |
Income statement | |||||
Turnover | 16,054,425,243 | 19,798,082,092 | 20,202,005,922 | 23,268,413,217 | 26,684,573,116.00 |
Cost of goods sold | 9,167,253,620 | 11,907,772,974 | 11,308,857,708 | 12,960,738,683 | 14,942,870,155.00 |
Gross profit | 6,887,171,623 | 7,890,309,118 | 8,893,148,214 | 10,307,674,534 | 11,741,702,961.00 |
Profit from operations | 3,754,727,749 | 4,615,536,767 | 5,198,704,396 | 6,144,784,666 | 7,208,225,885.00 |
Net profit before tax | 3,978,939,088 | 4,350,072,181 | 4,972,669,597 | 5,912,348,302 | 6,963,547,022.00 |
Net profit after tax | 2,897,710,641 | 3,125,019,992 | 3,637,997,573 | 4,250,580,863 | 5,186,436,869.00 |
Earnings Per Share | 10.94 | 9.76 | 8.74 | 10.26 | 10.8 |